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Abstract
Inhibitors against the p110δ isoform of PI3K have shown remarkable therapeutic efficacy in some 
human leukaemias1,2. Since p110δ is primarily expressed in leukocytes3, drugs against p110δ have 
not been considered for the treatment of solid tumours4. We report here that p110δ inactivation in 
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mice protects against a broad range of cancers, including non-haematological solid tumours. We 
demonstrate that p110δ inactivation in regulatory T cells (Treg) unleashes CD8+ cytotoxic T cells 
and induces tumour regression. Thus, p110δ inhibitors can break tumour-induced immune 
tolerance and should be considered for wider use in oncology.
PI3K p110δD910A (δD910A) mice in which endogenous p110δ kinase is inactive, present 
specific immune deficiencies5,6 but are not predisposed to cancer. To test if host p110δ 
activity affects tumour growth, we inoculated weakly immunogenic syngeneic cancer cell 
lines into δD910A mice. Compared to wild-type (WT) mice, δD910A mice were more resistant 
to B16 melanoma, with reduced tumour incidence and almost abrogated lymph node 
metastasis in those mice that developed tumours (Fig. 1a). Growth of Lewis lung carcinoma 
(LLC) and EL4 thymoma cells was also suppressed in δD910A mice (Fig. 1b,c). Similar 
observations were made with luciferase-labelled 4T1 breast cancer cells injected into the 
mammary fat pad. At sacrifice, δD910A mice showed reduced mass and luciferase activity of 
the primary 4T1 tumour (Fig. 1d) and lower metastasis (Fig. 1e). In WT mice, 4T1 tumours 
were detected by day 10 and grew progressively until day 30, at which point the mice 
became moribund (Fig. 1f). In some δD910A mice, 4T1 tumours grew initially, but then 
started to regress from day 15-20 onwards (Fig. 1f). Across 10 independent experiments, 
97% (71/73) of WT mice had an observable cancer mass at the end of study, compared to 
65% (43/66) of δD910A mice, with a median survival time of 23 and 40 days in WT and 
δD910A mice, respectively (Fig. 1g).
Effective tumour immunity is limited by Treg-mediated immune suppression7. δD910A mice 
show enhanced FoxP3+CD4+ Treg in the thymus but impaired subsequent Treg maintenance 
and functionality in the periphery8. δD910A Treg also produce less IL-10 and express lower 
levels of CD38, but show normal expression of most ‘Treg-signature’ genes, including 
FoxP3, CD25, CTLA4 and ICOS8,9. We therefore considered that reduced Treg function in 
δD910A mice might lead to enhanced tumour resistance. FoxP3+CD4+ Treg in the draining 
lymph nodes of 4T1 tumour-bearing δD910A mice did not expand as robustly as in WT mice 
(Fig. 2a), however no consistent differences in Treg expansion were observed in the B16 or 
EL4 tumour models between naive and tumour-bearing mice of either genotype (not shown). 
To assess Treg function, we carried out adoptive Treg transfer experiments in EL4 tumour-
bearing mice. Transfer of WT Treg into δD910A mice restored EL4 tumour growth and 
suppressed the relative abundance of tumour-infiltrating CD8+ T cells (Fig. 2b). By contrast, 
the transfer of the same number of δD910A Treg into δD910A mice did not affect EL4 tumour 
growth (Fig. 2b), indicating a functional defect in δD910A Treg. FoxP3YFP-Crexδflox/flox mice 
in which p110δ was selectively deleted in Treg (by a Cre transgene expressed from the 
Foxp3 locus) did not display spontaneous autoimmune or inflammatory responses (not 
shown) but showed reduced growth of B16 cells (Fig. 2c) and extended survival time upon 
inoculation of EL4 cells, to an even greater extent than in δD910A mice (Fig. 2d). These data 
demonstrate that p110δ inactivation in Treg is both necessary and sufficient to confer 
tumour resistance. However, these data also revealed a potential negative impact of p110δ 
inhibition on effector T cells, since FoxP3YFP-Crexδflox/flox mice were more cancer-resistant 
than δD910A mice (Fig. 2d). We therefore investigated the effect of p110δ inactivation on 
CD4 and CD8 effector T cells in the context of an ongoing tumour response.
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Depletion of CD8+ T cells but not of CD4+ T cells on day 10 after 4T1 inoculation in 
δD910A mice eliminated cancer protection (Fig. 3a,b). These data show that CD8+ T cells are 
responsible for restricting tumour growth in δD910A mice, but do not exclude an accessory 
role for CD4+ T cells. In line with published data5, naive WT mice had higher relative 
numbers of activated/memory CD44highCD4+ and CD44highCD8+ T cells than δD910A mice 
(Extended Data Fig. 1a). Upon 4T1 inoculation in WT mice, the relative numbers of these 
cells were either enhanced (tumour-draining lymph nodes) or reduced (blood and spleen), 
but in δD910A mice showed a trend towards expansion (Extended Data Fig. 1a), indicating 
that δD910A mice are capable of mounting both CD4+ and CD8+ T cell responses against 
4T1 tumours. WT and δD910A splenocytes from tumour-bearing mice, incubated in vitro 
with mitomycin C-treated 4T1 cells, generated equivalent cytotoxic activity against 4T1, 
with no specific lysis of LLC (Fig. 3c). Compared to WT cultures, δD910A cultures contained 
similar proportions of CD4 and CD8 T cell subsets (Extended Data Fig. 1b), with a reduced 
frequency of activated/memory CD44highCD4+ cells (Fig. 3d) and unaffected frequency of 
CD44high CD8+ cells (Fig. 3d). Interestingly, despite this reduced proportion of δD910A 
CD44highCD4+ cells, the frequency of IFNγ+ CD4+ cells in PMA/ionomycin-stimulated 
cultures of splenocytes from 4T1 tumour-bearing mice was unaffected by p110δ inactivation 
(Fig. 3e), with the frequency of IFNγ+ CD8+ cells even enhanced upon p110δ inactivation 
(Fig. 3e). Upon inoculation with LLC-OVA, WT and δD910A mice generated similar levels 
of tumour-infiltrating OVA-specific CD8+ T cells (Fig. 3f), showing that systemic in vivo 
inactivation of p110δ does not impede the development or recruitment of antigen-specific 
anti-tumour CD8+ cells.
To test the intrinsic ability of δD910A CD8 T cells to eliminate tumours, we crossed δD910A 
mice to OT-I transgenic mice which carry an OVA-specific MHC class I-restricted TCR 
transgene. In vitro generated δD910A OT-I CTLs were less efficient than WT OT-I CTLs at 
EL4-OVA killing (Fig. 3g) and produced lower levels of cytotoxic mediators (Extended 
Data Fig. 1c). Pharmacological inactivation of p110δ during the in vitro CTL expansion of 
WT OT-I cells partially suppressed CTL function, in a manner indistinguishable from 
genetic inactivation of p110δ (Fig. 3g), whereas p110δ blockade during the killing phase 
itself did not affect CTL function (Fig. 3g). Despite these in vitro defects in δD910A OT-I 
CTLs, adoptive transfer of these cells in WT mice prior to challenge with EL4-OVA, 
provided equal cancer protection to inoculation of WT OT-I T cells (Fig. 3h), showing that 
in vivo CTL responses can remain competent in the absence of CD8 T cell-intrinsic p110δ 
activity. Taken together, these data indicate that p110δ inhibition impairs differentiation of 
CD8 T cells to become fully competent CTL; however, fully differentiated CTL do not seem 
to require p110δ activity to kill target cells and on balance, in the context of reduced Treg 
function in δD910A mice, can mediate effective anti-tumour activity.
CD4 T cells can also contribute to tumour elimination by promoting the activation of 
macrophages and NK cells or by direct lysis of MHC class II+ tumour cells10. Indeed, CD4+ 
T cells with enhanced PI3K activity are superior in their capacity to reject tumour growth, 
probably as a consequence of their increased production of IFNγ11. Conversely, δD910A OT-
II CD4 cells were less effective than WT OT-II cells in preventing EL4-OVA tumour 
growth (Fig. 3h), consistent with our previous finding that δD910A OT-II T cells produce less 
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IFNγ in vitro and in vivo12,13. Therefore, in the context of an otherwise normal immune 
system, δD910A CD4+ cells show inferior anti-tumour immunity. However, the production of 
IFNγ by CD4 and CD8 T cells from 4T1 tumour-bearing δD910A mice, where Treg are also 
defective, appeared to be intact (Fig. 3e), suggesting that p110δ inhibition can affect the 
balance between regulatory and effector CD4+ T cells such that the effector cells prevail in 
the context of anti-tumour responses.
A salient feature of CD4 and CD8 T cells is the ability to raise a more potent and rapid 
immune response to subsequent exposure to cognate antigen. Upon surgical removal of 4T1 
primary tumours when they had reached 9 mm diameter and established metastatic foci14, 
WT mice all succumbed to re-growth of the primary tumour and metastatic disease. In 
contrast, >50% of post-surgical δD910A mice showed survival extension beyond 100 days 
(Fig. 3i), demonstrating that p110δ inhibition can suppress cancer relapse and presumably 
metastatic cancer after surgery. δD910A mice which had remained tumour-free >200 days 
after surgery were cancer-resistant upon rechallenge with a higher 4T1 dose (Fig. 3j), 
suggesting that surgical intervention in δD910A mice supports the development of an 
effective memory anti-tumour response.
To assess the potential importance of p110δ in myeloid cells in cancer, we tested the impact 
of p110δ inactivation in Rag−/− mice. Rag−/− mice, which lack mature B and T cells, showed 
enhanced primary 4T1 tumour size and metastasis (Fig. 4a) compared to WT mice. 
Rag−/−xδD910A mice showed similar 4T1 primary tumour burden as Rag−/− mice (Fig. 4a) 
but had fewer metastatic lesions in lung (Fig. 4a) and liver (not shown), indicating that 
p110δ inactivation in a non-B/T cell lineage delays 4T1 tumour progression but is not 
sufficient to instigate tumour rejection. We next assessed the impact of p110δ inactivation 
on myeloid-derived suppressor cells (MDSCs), a heterogeneous population of bone marrow-
derived myeloid cells that co-express the CD11b and Gr1 surface markers and which play a 
prominent role in immune suppression in cancer15,16. Neutrophils are also CD11b+Gr1+ but 
are thought not to be immune-suppressive17. Upon inoculation with 4T1 cells, known to be 
potent MDSC inducers16,17, CD11b+Gr1high cells accumulated in the spleens of both WT 
and δD910A mice, even before tumours were palpable, and continued to differentially 
accumulate in both genotypes as tumours grew, correlating with tumour size (Fig. 4b). The 
Ly6C and Ly6G surface markers, which are both recognized by the Gr1 antibody, have been 
used to subdivide MDSCs into two CD11b+ subpopulations, namely monocytic (M)-
MDSCs (Ly6ChighLy6Glow) and polymorphonuclear (PMN)-MDSCs 
(Ly6C-/lowLy6Ghigh)17. Although neutrophils are difficult to differentiate from PMN-
MDSCs, here we designated the neutrophil population as Ly6Ghigh cells with intermediate/
high Ly6C expression (Fig. 4c, Extended Data Fig. 2a). PMN-MDSCs, predominant in 4T1 
tumour-bearing WT mice (Fig. 4c), were substantially reduced in δD910A mice, correlating 
with a relative increase in neutrophils in the latter (Fig. 4c). Interestingly, the number of 
PMN-MDSCs in spleens from 4T1 tumour-bearing mice correlated with the number of 
Tregs (Fig. 4d). Depletion of CD8+ cells in 4T1 tumour-bearing δD910A mice, which led to 
enhanced tumour growth (Fig. 3a,b), also led to increased PMN-MDSC numbers and 
reduced neutrophil numbers (Fig. 4e). It was therefore difficult to ascertain whether the 
reduced PMN-MDSC numbers in δD910A mice are a consequence of an intrinsic role for 
Ali et al. Page 4
Nature. Author manuscript; available in PMC 2015 July 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
p110δ in these cells or an indirect consequence of a reduced tumour burden in δD910A mice 
(Fig. 4b). In support of the former, WT PMN-MDSCs suppressed T cell proliferation in 
vitro, whereas MDSCs from δD910A mice with regressing tumours did not (Fig. 4f; Extended 
Data Fig. 2b). Neutrophils from both genotypes did not suppress T cell responses (Fig. 4f). 
Moreover, splenocytes from tumour-bearing δD910A mice showed reduced in vitro 
production of TGFβ, VEGF and IL-6 (Fig. 4g), each of which can contribute to immune 
suppression and/or tumour growth15,16.
Administration of PI-3065, a small molecule inhibitor with selectivity for p110δ (Extended 
Data Fig. 3a,b and Extended Data Table 1), also suppressed 4T1 tumour growth and 
metastasis, to a similar extent as genetic inactivation of p110δ, marked by initial tumour 
progression, followed by tumour regression (Fig. 5a; Extended Data Fig. 3c,d). Of interest, 
4T1 do not express detectable levels of p110δ (Extended Data Fig. 3e) and are not growth-
inhibited in vitro by PI-3065 (Extended Data Fig. 3f). Long-term administration of PI-3065 
to mice was well-tolerated and did not induce weight loss (Extended Data Fig. 3g).
We next tested the impact of PI-3056 in the KPC model of pancreatic ductal 
adenocarcinoma (PDAC), which expresses endogenous mutant KrasG12D and p53R172H 
genes in Pdx1+ pancreatic cells. KPC mice were left to develop palpable disease before 
treatment with vehicle or PI-3065 was commenced. Under these therapeutic conditions, 
PI-3065 prolonged survival and reduced the incidence of metastases and other disease-
associated pathologies (Fig. 5b). The relative abundance of peripheral Treg in lymph nodes 
after 7 days of treatment was reduced (Fig. 5c), correlating with higher levels of 
CD44highCD8+ lymphocytes in the draining lymph nodes (Fig. 5d) and relatively more 
infiltrating CD8+ T cells in pancreatic lesions 14 days after treatment (Fig. 5e). These data 
indicate that therapeutic targeting of p110δ can promote immune-mediated elimination of 
cancer.
Concerns have been raised about inhibiting p110δ in cancer as this might impair CTLs and 
negatively impact on cancer immune surveillance4,18. Our data show that although p110δ 
blockade reduces the effectiveness of CTLs, it also overrides Treg- and probably also 
MDSC-mediated suppression of anti-tumour immune responses, enabling even weakened 
CTLs to successfully attack tumours. Thus, p110δ is apparently more essential for 
regulatory rather than effector T cell responses against cancer cells. In addition, inhibition of 
the PI3K pathway in CD8 T cells may help maintain them in a stem-cell like state19 with 
enhanced potential for generating durable anti-tumour responses. Consistent with this 
notion, δD910A mice resisted tumour rechallenge following surgical removal of the first 
tumour. The p110δ inhibitor Idelalisib has shown impressive therapeutic impact in chronic 
lymphocytic leukaemia (CLL) and non-Hodgkin’s lymphoma1,2. In CLL, p110δ blockade 
interferes with stroma-derived survival and adhesion signals supporting the tumour cells4, 
but it is unclear if this fully explains the effectiveness of p110δ inhibition. Our finding that 
p110δ inhibition can unlock adaptive anti-tumour responses provides a potential additional 
mechanism for the efficacy of p110δ blockade in CLL, and add to the emerging rationale for 
targeting PI3K in the tumour stroma4, to dampen inflammation (p110γ)20 and angiogenesis 
(p110α)21.
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Tumour-induced immune suppression constitutes an important barrier for effective anti-
tumour immunity and immunotherapy in cancer. Our work suggests that p110δ inhibitors, 
by disrupting the function of Treg and possibly of MDSCs, have the potential to shift the 
balance from immune tolerance towards effective anti-tumour immunity. This provides a 
rationale for p110δ inhibition both in solid and haematological cancer, possibly as an 
adjuvant to cancer vaccines, adoptive cell therapy, or other strategies that promote tumour-
specific immune responses.
METHODS SUMMARY
All animal procedures were in compliance with institutional animal care and use committee 
guidelines. Details of procedures and reagents are described in Methods.
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Extended Data
Extended Data Figure 1. Impact of p110δ inactivation on CD4 and CD8 T cells in mice with 4T1 
or EL4 tumours
a, Levels of CD44highCD4+ and CD44highCD8+ T cells in the indicated immune 
compartments of naive and 4T1 tumour-bearing on day 26 after inoculation in WT or δD910A 
mice. b, Distribution of cells on day 5 of culture of splenocytes, isolated from 4T1 tumour-
bearing WT and δD910A mice 21 days after inoculation, in the presence of mitomycin-treated 
4T1 cells. c, Gene expression in CTLs derived from splenocytes from WT and δD910A OT-I 
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mice, cultured in the presence of SIINFEKL OVA peptide and IL2. GzmA, granzyme A; 
GzmB, granzyme B, Prf1, perforin and (FasL or CD95L) Fas ligand. Expression levels are 
presented relative to β2-microglobulin. a-b, Statistically significant differences are indicated 
by * (P < 0.05) or ** (P < 0.01), as determined by the non-parametric Mann-Whitney t test. 
Between brackets: number of mice used per experiment. Each dot represents an individual 
mouse.
Extended Data Figure 2. Impact of p110δ inactivation on myeloid cells in 4T1 tumours
a, Gating strategy used to identify myeloid cell subsets. Splenic cells were gated on 
CD11bhigh cells followed by Ly6C and Ly6G gating. FSC, forward scatter; SSC, side scatter 
(top panel). Frequency of CD11b+ cells in the spleen of WT and δD910A naïve mice and in 
4T1 tumour-bearing mice on day 21 after inoculation (bottom panel). b, [3H]-Thymidine 
incorporation in co-cultures of splenocytes and purified myeloid cells, in combinations as 
indicated, with or without stimulation with anti-CD3 antibodies. Cultures were made using 
cells derived from individual mice. Error bars represent standard deviation from the mean of 
biological replicates. Statistically significant differences are indicated by * (P < 0.05) or ** 
(P < 0.01), as determined by the non-parametric Mann-Whitney t test. Between brackets: 
number of mice used per experiment. Each dot represents an individual mouse.
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Extended Data Figure 3. Characterisation of the p110δ-selective inhibitor PI-3065
a, PI-3065 structure and in vitro IC50 on selected PI3K family members. No significant 
activity against 72 protein kinases was observed at ≤ 10 μM in a KinaseProfiler assay 
(Millipore). b, Pharmacokinetic parameters of PI-3065. Mean (±SD) plasma concentration 
profile of PI-3065 following a single oral dose (75 mg/kg) administred per os (po) to female 
BALB/c mice. AUCinf, area under the curve, extrapolated to infinity; Cmax, highest 
observed plasma concentration; tmax, time at which Cmax occurred, QD; quaque die, every 
day. c, Growth of primary 4T1 tumours, inoculated in the breast fat pad, measured by 
calipers and expressed as tumour volume. Mice were dosed per os with vehicle or PI-3065 
(75 mg/kg, daily) for 36 days. 105 tumour cells were inoculated 12 h post first dosing. d, 
Percentage of tumour-free mice upon continuous per os treatment of mice with vehicle or 
PI-3065 (25 mg/kg, twice daily) for 37 days, with tumour cells inoculated on day 7 of 
PI-3065 dosing. 15 mice were used for each genotype. e, Class I PI3K isoform expression in 
4T1 cells. f, Proliferation of 4T1 cells following a 4 h treatment with the indicated p110δ 
inhibitors, washing and MTS staining after 48 h culture. g, Percentage body weight change 
(from day 0) of 4T1 tumour-bearing mice upon daily per os administration of PI-3065 (75 
mg/kg) or vehicle for 36 consecutive days. Statistically significant differences are indicated 
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by * (P < 0.05) or ** (P < 0.01), as determined by the non-parametric Mann-Whitney t test. 
Between brackets: number of mice used per experiment.
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Figure 1. Impact of genetic inactivation of p110δ on tumour growth and metastasis
a, percentage of mice with visible B16 ear tumours (left) or lymph nodes metastasis (right). 
Photographs show B16 metastases in cervical lymph nodes and representative excised 
lymph nodes. b-d, primary tumour burden of the indicated tumour lines. e, 4T1 metastasis as 
detected by luciferase activity (left and middle panel) or histology (right panel), expressed 
as a percentage of the total number of tumour-bearing animals/group. f, Growth of primary 
4T1 tumours. g, Survival of 4T1 tumour-bearing mice. a-f, Statistically significant 
differences are indicated by * (P < 0.05) or ** (P < 0.01), as determined by the non-
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parametric Mann-Whitney t test. Between brackets: number of mice used per experiment. 
Each dot represents an individual mouse.
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Figure 2. Inactivation of p110δ in Treg is sufficient to confer cancer resistance
a, Relative and total numbers of Treg in the draining lymph nodes of naive and 4T1 tumour-
bearing mice. b, Impact of adoptive transfer of Treg into δD910A mice on EL4 tumour wet 
weight and tumour-infiltrating CD8+ T cells. c, Number of mice with visible B16 tumours 
and B16 tumour weight in mice of the indicated genotype. d, Survival of EL4 tumour-
bearing mice of the indicated genotype. a-c, Statistically significant differences are indicated 
by * (P<0.05) or ** (P<0.01), as determined by the non-parametric Mann-Whitney t test or 
Anova. Between brackets: number of mice used per experiment. Each dot represents an 
individual mouse.
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Figure 3. Impact of p110δ inactivation on T cell-mediated anti-tumour immunity
a, Growth of 4T1 in δD910A mice injected with antibodies to CD4 or CD8. Arrow indicates 
the time of antibody injection. b, Metastasis in CD4 or CD8 T cell-depleted 4T1 tumour-
bearing δD910A mice. c, In vitro cytotoxic activity of splenocytes, isolated from 4T1 tumour-
bearing WT and δD910A mice 21 days after inoculation and cultured for 4 days with 
mitomycin-treated 4T1 cells. E/T, effector to target (4T1 or LLC) ratio. d, Frequency of 
CD44high CD4+ and CD8+ T cells in splenocytes from 4T1 tumour-bearing mice cultured 
for 5 days with mitomycin-treated 4T1 cells. e, Frequency of IFNγ+ T cells after 16h PMA
+ionomycin stimulation of splenocytes from WT and δD910A 4T1 tumour-bearing mice. f, 
Relative levels of tumour-infiltrating CD3+ lymphocytes and OVA-specific CD8+ T cells in 
LLC-OVA tumours in WT or δD910A mice. g, In vitro cell killing of a 1:1 EL4-OVA:EL4 
mix following 24h incubation with CTL from WT or a δD910A OT-I mice (at an E/T ratio of 
10:1), incubated with or without the p110δ inhibitor IC87114 during the 8 day expansion 
phase, the 24h killing phase, or both. Cell killing efficiency is expressed as the ratio of EL4-
OVA cells over EL4 cells remaining after incubation with effector cells. h, Effect of 
adoptive transfer in WT mice of OT-I CD8+ or OT-II CD4+ cells on growth of subsequently 
inoculated EL4-OVA. i, Survival of post-surgical 4T1 tumour-bearing mice. j, Survival of 
δD910A mice which had remained tumour-free >200 days after surgery, and of naïve WT 
mice, following injection of 10,000 4T1 cells. Statistics are as described in the legend to 
Figure 1.
Ali et al. Page 17
Nature. Author manuscript; available in PMC 2015 July 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 4. Impact of p110δ inactivation on myeloid cells in 4T1 tumour-bearing mice
a, 4T1 primary tumour growth and lung metastasis in WT, δD910A, Rag−/− and Rag−/− 
xδD910A mice. b, 4T1 tumour growth and total numbers of splenic CD11b+Gr1high myeloid 
cells in WT and δD910A mice. c, Gating strategy used to identify myeloid cell subsets and 
frequency of splenic PMN-MDSCs and neutrophils of naïve and 4T1 tumour-bearing WT 
and δD910A mice. d, Spearman correlation between accumulation of splenic PMN-MDSCs 
and Treg in WT or δD910A mice. e, Impact of depleting CD8+ T cells in δD910A mice on 4T1 
tumour burden and presence of splenic myeloid cell populations. f, Impact of purified 
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splenic myeloid cells on proliferation of anti-CD3-stimulated WT T cells. g, Cytokine 
production by splenocytes from 4T1 tumour-bearing (30 days after inoculation) from WT or 
δD910A mice, individually cultured for 4 days. Statistics are as described in the legend to 
Figure 1.
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Figure 5. Impact of pharmacological inactivation of p110δ on tumour growth and T cell 
responses
a, Mice, dosed with vehicle or PI-3065 (75 mg/kg, daily) for 36 days and inoculated with 
105 4T1 cells 12h post first dosing, were assessed for tumour growth by luciferase imaging 
(first panel), tumour weight (second panel) or luciferase activity in tumours excised 35 days 
after inoculation (third panel). Incidence of 4T1 metastasis (fourth panel), as detected by 
H&E staining and histology, expressed as percentage of the total number of tumour-bearing 
animals per group. b, Impact of PI-3065 (75 mg/kg) on KPC mouse survival (left) and 
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macrometastases (as detected by H&E staining) and cancer-associated pathology (right). c, 
Proportion of Treg (% of CD4+) in the draining lymph nodes of KPC mice administered 
vehicle or PI-3065. d, Proportion of CD44high T cells (% of CD8+) in the draining lymph 
nodes of KPC mice administered vehicle or PI-3065. e, Relative numbers of CD8+ T cells 
(% of CD45+) in normal pancreas and PDAC lesions of KPC mice treated or not with 
PI-3065. Statistics are as described in the legend to Figure 1.
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